Table 3.
Predictor | Urinary function
|
Erectile function
|
||||
---|---|---|---|---|---|---|
HR | 95% CI | p value | HR | 95% CI | p value | |
|
|
|||||
Functional domain score at 12 mo† | 1.20 | 1.12–1.28 | <0.0001 | 1.10 | 1.08–1.13 | <0.0001 |
Patient age | 0.96 | 0.94–0.99 | 0.002 | 0.98 | 0.96–1.00 | 0.045 |
Preoperative PSA | 1.00 | 0.96–1.04 | 0.9 | 1.01 | 0.98–1.04 | 0.5 |
Body mass index | 1.02 | 0.98–1.06 | 0.3 | 0.97 | 0.94–1.00 | 0.079 |
Comorbidities | ||||||
0 | Ref. | Ref. | ||||
1 | 1.26 | 0.83–1.92 | 0.3 | 0.93 | 0.67–1.29 | 0.7 |
2 | 0.94 | 0.59–1.49 | 0.8 | 0.71 | 0.46–1.10 | 0.12 |
≥3 | 1.13 | 0.63–2.03 | 0.7 | 1.19 | 0.71–2.02 | 0.5 |
Nerve-sparing status | ||||||
None | Ref. | |||||
Unilateral | 0.98 | 0.53–1.83 | 1.0 | 1.91 | 0.74–4.96 | 0.2 |
Bilateral | 1.06 | 0.62–1.83 | 0.8 | 2.32 | 0.93–5.77 | 0.070 |
Pathologic Gleason score | ||||||
≤6 | Ref. | Ref. | ||||
7 | 1.19 | 0.77–1.83 | 0.4 | 1.27 | 0.87–1.86 | 0.2 |
≥8 | 1.22 | 0.55–2.74 | 0.6 | 1.23 | 0.57–2.68 | 0.6 |
Pathologic T stage | ||||||
T2 | Ref. | Ref. | ||||
T3 or higher | 0.91 | 0.64–1.30 | 0.6 | 1.05 | 0.75–1.46 | 0.8 |
CI = confidence interval; HR = hazard ratio; IIEF-6 = International Index of Erectile Function; PSA = prostate-specific antigen; Ref. = reference.
In patients who have urinary incontinence or erectile dysfunction at 12 mo after radical prostatectomy.
For erectile function, the modified IIEF-6 scoring was applied to the functional domain score at 12 mo.